JPWO2019209692A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019209692A5 JPWO2019209692A5 JP2020558958A JP2020558958A JPWO2019209692A5 JP WO2019209692 A5 JPWO2019209692 A5 JP WO2019209692A5 JP 2020558958 A JP2020558958 A JP 2020558958A JP 2020558958 A JP2020558958 A JP 2020558958A JP WO2019209692 A5 JPWO2019209692 A5 JP WO2019209692A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- compound
- optionally substituted
- azaspiro
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 126
- 150000001875 compounds Chemical class 0.000 description 60
- -1 azetidyl Chemical group 0.000 description 54
- 125000000217 alkyl group Chemical group 0.000 description 29
- 125000001424 substituent group Chemical group 0.000 description 18
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 17
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 17
- 125000001072 heteroaryl group Chemical group 0.000 description 17
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 17
- 125000003118 aryl group Chemical group 0.000 description 16
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 15
- 239000000126 substance Substances 0.000 description 15
- 229910052731 fluorine Inorganic materials 0.000 description 11
- 150000003839 salts Chemical class 0.000 description 11
- 229910052801 chlorine Inorganic materials 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 125000000753 cycloalkyl group Chemical group 0.000 description 9
- 239000008194 pharmaceutical composition Substances 0.000 description 9
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 8
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 8
- 229910052736 halogen Inorganic materials 0.000 description 8
- 150000002367 halogens Chemical class 0.000 description 8
- 125000000623 heterocyclic group Chemical group 0.000 description 7
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 7
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 6
- 125000002757 morpholinyl group Chemical group 0.000 description 6
- 125000004193 piperazinyl group Chemical group 0.000 description 6
- 125000003226 pyrazolyl group Chemical group 0.000 description 6
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
- 125000005936 piperidyl group Chemical group 0.000 description 5
- CZSRXHJVZUBEGW-UHFFFAOYSA-N 1,2-thiazolidine Chemical compound C1CNSC1 CZSRXHJVZUBEGW-UHFFFAOYSA-N 0.000 description 4
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 4
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 4
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 4
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 4
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 description 4
- 229960002707 bendamustine Drugs 0.000 description 4
- 229960004397 cyclophosphamide Drugs 0.000 description 4
- 229960004679 doxorubicin Drugs 0.000 description 4
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 4
- 229960005420 etoposide Drugs 0.000 description 4
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 4
- 229960005277 gemcitabine Drugs 0.000 description 4
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 4
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 4
- 229960004942 lenalidomide Drugs 0.000 description 4
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 4
- 229960004618 prednisone Drugs 0.000 description 4
- 125000004929 pyrrolidonyl group Chemical group N1(C(CCC1)=O)* 0.000 description 4
- 229960004641 rituximab Drugs 0.000 description 4
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 4
- 229960004528 vincristine Drugs 0.000 description 4
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 4
- 125000001715 oxadiazolyl group Chemical group 0.000 description 3
- 125000002971 oxazolyl group Chemical group 0.000 description 3
- 125000003373 pyrazinyl group Chemical group 0.000 description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 description 3
- 125000001113 thiadiazolyl group Chemical group 0.000 description 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 2
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 2
- 125000005962 1,4-oxazepanyl group Chemical group 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 1
- YUCFVHQCAFKDQG-UHFFFAOYSA-N fluoromethane Chemical compound F[CH] YUCFVHQCAFKDQG-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024041949A JP2024073590A (ja) | 2018-04-23 | 2024-03-18 | 置換された４－アミノイソインドリン－１，３－ジオン化合物、及びリンパ腫の治療のためのそれらの使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862661525P | 2018-04-23 | 2018-04-23 | |
| US62/661,525 | 2018-04-23 | ||
| PCT/US2019/028471 WO2019209692A1 (fr) | 2018-04-23 | 2019-04-22 | Composés de 4-aminoisoindoline-1,3-dione substitués et leur utilisation pour traiter un lymphome |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024041949A Division JP2024073590A (ja) | 2018-04-23 | 2024-03-18 | 置換された４－アミノイソインドリン－１，３－ジオン化合物、及びリンパ腫の治療のためのそれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021523885A JP2021523885A (ja) | 2021-09-09 |
| JPWO2019209692A5 true JPWO2019209692A5 (fr) | 2022-05-02 |
| JP7458324B2 JP7458324B2 (ja) | 2024-03-29 |
Family
ID=66641467
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020558958A Active JP7458324B2 (ja) | 2018-04-23 | 2019-04-22 | 置換された４－アミノイソインドリン－１，３－ジオン化合物、及びリンパ腫の治療のためのそれらの使用 |
| JP2024041949A Pending JP2024073590A (ja) | 2018-04-23 | 2024-03-18 | 置換された４－アミノイソインドリン－１，３－ジオン化合物、及びリンパ腫の治療のためのそれらの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024041949A Pending JP2024073590A (ja) | 2018-04-23 | 2024-03-18 | 置換された４－アミノイソインドリン－１，３－ジオン化合物、及びリンパ腫の治療のためのそれらの使用 |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US11358952B2 (fr) |
| EP (2) | EP3784663B1 (fr) |
| JP (2) | JP7458324B2 (fr) |
| KR (1) | KR20210003103A (fr) |
| CN (2) | CN113214220B (fr) |
| AR (1) | AR114803A1 (fr) |
| AU (2) | AU2019261273B2 (fr) |
| BR (1) | BR112020021552B1 (fr) |
| CA (1) | CA3096404A1 (fr) |
| CL (1) | CL2020002696A1 (fr) |
| CO (1) | CO2020012824A2 (fr) |
| DK (1) | DK3784663T3 (fr) |
| EA (1) | EA202092248A1 (fr) |
| ES (1) | ES2959622T3 (fr) |
| FI (1) | FI3784663T3 (fr) |
| HR (1) | HRP20231199T1 (fr) |
| HU (1) | HUE064340T2 (fr) |
| IL (1) | IL277435B1 (fr) |
| LT (1) | LT3784663T (fr) |
| MX (2) | MX2020011183A (fr) |
| PE (1) | PE20211375A1 (fr) |
| PL (1) | PL3784663T3 (fr) |
| PT (1) | PT3784663T (fr) |
| RS (1) | RS64663B1 (fr) |
| SG (1) | SG11202009237XA (fr) |
| SI (1) | SI3784663T1 (fr) |
| TW (1) | TWI814815B (fr) |
| WO (1) | WO2019209692A1 (fr) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR119715A1 (es) | 2019-04-12 | 2022-01-05 | Celgene Corp | Métodos para tratar linfoma no hodgkin con el uso de 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)bencil)amino)isoindolin-1,3-diona |
| AU2020372334A1 (en) | 2019-10-21 | 2022-05-05 | Celgene Corporation | Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined use |
| BR112022007468A2 (pt) | 2019-10-21 | 2022-07-12 | Celgene Corp | Composições farmacêuticas compreendendo (s)-2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)benzil)amino)isoindolina-1,3-diona e métodos para usar as mesmas |
| AU2020372333A1 (en) * | 2019-10-21 | 2022-04-28 | Celgene Corporation | Methods for treating a hematological cancer and the use of companion biomarkers for 2-(2,6-Dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione |
| EP4048666A1 (fr) * | 2019-10-21 | 2022-08-31 | Celgene Corporation | Formes solides comprenant (s)-2-(2,6-dioxopipéridin-3-yl)-4-((2-fluoro-4-((3-morpholinoazétidin-1-yl)méthyl)benzyl)amino)isoindoline-1,3-dione et sels de celles-ci, compositions les comprenant et leur utilisation |
| AU2020369497A1 (en) * | 2019-10-21 | 2022-05-19 | Celgene Corporation | Methods of treating chronic lymphocytic leukemia using 2-(2,6-dioxopiperidin-3yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1. 3-dione |
| LT4048278T (lt) | 2019-10-21 | 2023-12-11 | Celgene Corporation | Hematologinio piktybinio naviko gydymo būdai, panaudojant 2-(2,6- dioksopiperidin-3-il)-4-((2-fluor-4-((3-morfolinoazetidin-1-il)metil)benzil) amino)izoindolin-1,3-dioną |
| CA3168456A1 (fr) * | 2020-01-20 | 2021-07-29 | Kangpu Biopharmaceuticals, Ltd. | Derive d'isoindoline, composition pharmaceutique et son utilisation |
| TW202241872A (zh) * | 2021-01-05 | 2022-11-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 稠雜環基取代的環己二醯亞胺衍生物、其製備方法及其在醫藥上的應用 |
| CA3208313A1 (fr) | 2021-01-13 | 2022-07-21 | Monte Rosa Therapeutics Ag | Composes d'isoindolinone |
| JP2024513054A (ja) | 2021-03-29 | 2024-03-21 | ジュノー セラピューティクス インコーポレイテッド | リンパ腫の治療のためのｃａｒ ｔ細胞療法および免疫調節化合物の組合せ |
| CA3210782A1 (fr) * | 2021-04-21 | 2022-10-27 | Poliana Alves Patah | Methodes de traitement d'un lymphome a cellules b a l'aide d'une polytherapie |
| WO2022226011A1 (fr) | 2021-04-21 | 2022-10-27 | Celgene Corporation | Méthodes de traitement d'un lymphome non hodgkinien à l'aide de 2-(2,6-dioxopipéridin-3-yl)-4-(2-fluoro-4-((3-morpholinoazétidin-1-yl)méthyl)benzyl)amino)isoindoline-1,3-dione |
| KR20240024087A (ko) | 2021-06-21 | 2024-02-23 | 셀진 코포레이션 | (s)-2-(2,6-디옥소피페리딘-3-일)-4-((2-플루오로-4-((3-모르폴리노아제티딘-1-일)메틸)벤질)아미노)이소인돌린-1,3-디온의제조 프로세스 |
| WO2023025136A1 (fr) * | 2021-08-27 | 2023-03-02 | 杭州格博生物医药有限公司 | Composé d'isoindolinone et son utilisation |
| WO2023220641A2 (fr) | 2022-05-11 | 2023-11-16 | Juno Therapeutics, Inc. | Méthodes et utilisations associées à une thérapie par lymphocytes t et leur production |
| WO2023220655A1 (fr) | 2022-05-11 | 2023-11-16 | Celgene Corporation | Méthodes pour surmonter la résistance aux médicaments par ré-sensibilisation de cellules cancéreuses à un traitement avec une thérapie antérieure par l'intermédiaire d'un traitement avec une thérapie par lymphocytes t |
| CN117088864A (zh) * | 2022-05-13 | 2023-11-21 | 广州智药生物科技有限公司 | 一种苯并[d]异恶唑类化合物及其应用 |
| WO2024097905A1 (fr) | 2022-11-02 | 2024-05-10 | Celgene Corporation | Méthodes de traitement au moyen d'une thérapie par lymphocytes t et d'une thérapie d'entretien par agent immunomodulateur |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7091353B2 (en) | 2000-12-27 | 2006-08-15 | Celgene Corporation | Isoindole-imide compounds, compositions, and uses thereof |
| US20030045552A1 (en) * | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
| EP1505973B1 (fr) | 2002-05-17 | 2010-03-03 | Celgene Corporation | Combinaisons pour le traitement du myélome multiple |
| US7563810B2 (en) | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
| CN100398534C (zh) | 2003-09-15 | 2008-07-02 | 天津和美生物技术有限公司 | 合成酞胺哌啶酮及其衍生物的方法 |
| US20050143344A1 (en) | 2003-12-30 | 2005-06-30 | Zeldis Jerome B. | Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases |
| AU2005282728A1 (en) | 2004-09-03 | 2006-03-16 | Celgene Corporation | Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines |
| CA2586950A1 (fr) | 2004-11-12 | 2006-05-18 | Celgene Corporation | Procedes et compositions utilisant des composes immunomodulateurs pour traiter et gerer des maladies parasitaires |
| JP5366544B2 (ja) | 2005-06-30 | 2013-12-11 | セルジーン コーポレイション | ４−アミノ−２−（２，６−ジオキソピペリジン−３−イル）イソインドリン−１，３−ジオン化合物を調製するための方法 |
| UA91560C2 (ru) | 2005-08-31 | 2010-08-10 | Селджин Корпорэйшн | Соединения ряда изоиндолимидов, их композиция и применение |
| EP1974013A2 (fr) | 2005-12-29 | 2008-10-01 | Anthrogenesis Corporation | Composition améliorée pour la collecte et la conservation de cellules souches placentaires et procédés d'utilisation de cette composition |
| US20080064876A1 (en) | 2006-05-16 | 2008-03-13 | Muller George W | Process for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione |
| MX2009001989A (es) | 2006-08-30 | 2009-03-09 | Celgene Corp | Compuestos de isoindolina 5-substituidos. |
| US8877780B2 (en) | 2006-08-30 | 2014-11-04 | Celgene Corporation | 5-substituted isoindoline compounds |
| ZA200901852B (en) * | 2006-09-15 | 2010-06-30 | Celgene Corp | N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same |
| US8153659B2 (en) | 2007-03-20 | 2012-04-10 | Celgene Corporation | 4′-O-substituted isoindoline derivatives and compositions comprising and methods of using the same |
| AU2008325140A1 (en) | 2007-11-08 | 2009-05-14 | Celgene Corporation | Use of immunomodulatory compounds for the treatment of disorders associated with endothelial dysfunction |
| JP5603876B2 (ja) | 2008-10-29 | 2014-10-08 | セルジーン コーポレイション | 癌の治療に使用するためのイソインドリン化合物 |
| RS56232B1 (sr) * | 2010-02-11 | 2017-11-30 | Celgene Corp | Derivati arilmetoksi izoindolina i kompozicije koje ih obuhvataju i postupci njihove primene |
| US20110312996A1 (en) | 2010-05-17 | 2011-12-22 | Intermune, Inc. | Novel inhibitors of hepatitis c virus replication |
| CN105061438B (zh) * | 2010-06-23 | 2017-07-04 | 韩美科学株式会社 | 用于抑制酪氨酸激酶活性的稠合嘧啶衍生物 |
| US20140206629A1 (en) | 2011-02-17 | 2014-07-24 | Rhode Island Hospital | Stromal Derived Factor Inhibition And CXCR4 Blockade |
| CA2867134C (fr) | 2011-03-28 | 2019-05-07 | Sheila Dewitt | Composes de 2',6'-dioxo-3'-deutero-piperidin-3-yl-isoindoline |
| WO2016040449A1 (fr) | 2014-09-10 | 2016-03-17 | Raze Therapeutics, Inc. | Inhibiteurs de la 3-phosphoglycérate déshydrogénase) et leurs utilisations |
| EP3214081B1 (fr) * | 2014-10-30 | 2020-07-08 | Kangpu Biopharmaceuticals, Ltd. | Dérivé d'isoindoline, son intermédiaire, son procédé de préparation, sa composition pharmaceutique et son utilisation |
| EP3256470B1 (fr) | 2014-12-23 | 2023-07-26 | Dana-Farber Cancer Institute, Inc. | Procédés pour induire la dégradation ciblée de protéines par des molécules bifonctionnelles |
| WO2017007612A1 (fr) | 2015-07-07 | 2017-01-12 | Dana-Farber Cancer Institute, Inc. | Procédés pour induire la dégradation ciblée de protéines par des molécules bifonctionnelles |
| WO2017024317A2 (fr) | 2015-08-06 | 2017-02-09 | Dana-Farber Cancer Institute, Inc. | Procédés pour induire la dégradation de protéine ciblée par des molécules bifonctionnelles |
| KR102053556B1 (ko) * | 2015-09-29 | 2020-01-08 | 강푸 바이오파마슈티칼즈 리미티드 | 약물 조성물 및 이의 응용 |
| WO2017121388A1 (fr) * | 2016-01-14 | 2017-07-20 | 康朴生物医药技术（上海）有限公司 | Dérivé de quinazolinone, son procédé de préparation, composition pharmaceutique, et applications associées |
| DK3429591T3 (da) | 2016-03-16 | 2023-06-19 | Kura Oncology Inc | Substituerede thieno[2,3-D]pyrimidin-derivater som inhibitorer af Menin-MLL og fremgangsmåder til anvendelse |
| MX2018012174A (es) | 2016-04-06 | 2019-07-08 | Univ Michigan Regents | Degradantes de proteina homologa de proteina murina de cromosoma diminuto doble (mdm2). |
| WO2017197056A1 (fr) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Dégronimères ciblant un bromodomaine pour la dégradation de protéines cibles |
| CA3025805A1 (fr) | 2016-06-23 | 2017-12-28 | James Bradner | Degradation de la proteine a motif tripartie 24 (trim24) par conjugaison d'inhibiteurs de trim24 avec un ligand de la ligase e3 et procedes d'utilisation |
| US11285218B2 (en) | 2016-06-23 | 2022-03-29 | Dana-Farber Cancer Institute, Inc. | Degradation of bromodomain-containing protein 9 (BRD9) by conjugation of BRD9 inhibitors with E3 ligase ligand and methods of use |
| US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
| AU2017341723B2 (en) | 2016-10-11 | 2021-12-16 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| CA3041840A1 (fr) | 2016-10-28 | 2018-05-03 | Icahn School Of Medicine At Mount Sinai | Compositions et procedes pour le traitement du cancer a mediation par l'ezh2 |
| EP3535254A4 (fr) | 2016-11-01 | 2020-06-24 | Cornell University Cornell Center For Technology, Enterprise & Commercialization ("CCTEC") | Composés pour la dégradation de malt1 |
| EP3544957B1 (fr) | 2016-11-22 | 2024-05-29 | Dana-Farber Cancer Institute, Inc. | Dégradation de protéines kinases par conjugaison d'inhibiteurs de protéine kinase avec un ligand de la ligase e3 et procédés d'utilisation |
| RS64976B1 (sr) | 2016-12-01 | 2024-01-31 | Arvinas Operations Inc | Derivati tetrahidronaftalena i tetrahidroizohinolina kao degradatori estrogenih receptora |
| CA3045037A1 (fr) | 2016-12-08 | 2018-06-14 | Icahn School Of Medicine At Mount Sinai | Compositions et methodes pour le traitement du cancer a mediation par cdk4/6 |
| CN107056772A (zh) | 2017-01-23 | 2017-08-18 | 中国药科大学 | 基于cereblon配体诱导BET降解的双功能分子及其制备和应用 |
| BR112019015312A2 (pt) | 2017-01-26 | 2020-03-10 | Arvinas Operations, Inc. | Moduladores da proteólise pelo receptor de estrogênio e métodos de uso associados |
| JP2020506922A (ja) | 2017-01-31 | 2020-03-05 | アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． | セレブロンリガンド、およびセレブロンリガンドを含有する二官能性化合物 |
| CA3053805C (fr) | 2017-02-13 | 2020-06-30 | Kangpu Biopharmaceuticals, Ltd. | Association medicamenteuse pour le traitement du cancer de la prostate, composition pharmaceutique et methode de traitement |
| CN108929307A (zh) * | 2017-05-22 | 2018-12-04 | 苏州偶领生物医药有限公司 | 一类异吲哚酮-酰亚胺环-1,3-二酮-2-烯化合物、其组合物和用途 |
| AU2018301335B2 (en) * | 2017-07-10 | 2022-09-15 | Celgene Corporation | Antiproliferative compounds and methods of use thereof |
| EP3652329B1 (fr) | 2017-07-12 | 2023-10-04 | Dana-Farber Cancer Institute, Inc. | Composés pour la dégradation de la protéine tau |
| CN107698575A (zh) | 2017-09-26 | 2018-02-16 | 中国药科大学 | cereblon配体介导的新型BET蛋白降解的双功能分子及其制备和应用 |
| CN108715585A (zh) | 2018-04-23 | 2018-10-30 | 中国药科大学 | 苯基联三氮唑类mll1-wdr5蛋白-蛋白相互作用抑制剂 |
| US11819532B2 (en) | 2018-04-23 | 2023-11-21 | Hoffmann-La Roche Inc. | Peptide macrocycles against Acinetobacter baumannii |
| CN108690020A (zh) | 2018-07-04 | 2018-10-23 | 清华大学 | 一种靶向降解bet蛋白的化合物及其应用 |
| CN108794453A (zh) | 2018-07-05 | 2018-11-13 | 清华大学 | 一种靶向降解fak蛋白的化合物及其应用 |
-
2019
- 2019-04-22 PT PT197262256T patent/PT3784663T/pt unknown
- 2019-04-22 PL PL19726225.6T patent/PL3784663T3/pl unknown
- 2019-04-22 PE PE2020001622A patent/PE20211375A1/es unknown
- 2019-04-22 LT LTEPPCT/US2019/028471T patent/LT3784663T/lt unknown
- 2019-04-22 BR BR112020021552-0A patent/BR112020021552B1/pt active IP Right Grant
- 2019-04-22 TW TW108113978A patent/TWI814815B/zh active
- 2019-04-22 CA CA3096404A patent/CA3096404A1/fr active Pending
- 2019-04-22 EP EP19726225.6A patent/EP3784663B1/fr active Active
- 2019-04-22 EP EP23184388.9A patent/EP4272737A3/fr active Pending
- 2019-04-22 HR HRP20231199TT patent/HRP20231199T1/hr unknown
- 2019-04-22 CN CN202110419043.3A patent/CN113214220B/zh active Active
- 2019-04-22 EA EA202092248A patent/EA202092248A1/ru unknown
- 2019-04-22 RS RS20230890A patent/RS64663B1/sr unknown
- 2019-04-22 MX MX2020011183A patent/MX2020011183A/es unknown
- 2019-04-22 ES ES19726225T patent/ES2959622T3/es active Active
- 2019-04-22 IL IL277435A patent/IL277435B1/en unknown
- 2019-04-22 AU AU2019261273A patent/AU2019261273B2/en active Active
- 2019-04-22 SG SG11202009237XA patent/SG11202009237XA/en unknown
- 2019-04-22 SI SI201930632T patent/SI3784663T1/sl unknown
- 2019-04-22 WO PCT/US2019/028471 patent/WO2019209692A1/fr active Application Filing
- 2019-04-22 DK DK19726225.6T patent/DK3784663T3/da active
- 2019-04-22 FI FIEP19726225.6T patent/FI3784663T3/fi active
- 2019-04-22 JP JP2020558958A patent/JP7458324B2/ja active Active
- 2019-04-22 HU HUE19726225A patent/HUE064340T2/hu unknown
- 2019-04-22 KR KR1020207029644A patent/KR20210003103A/ko not_active Application Discontinuation
- 2019-04-22 AR ARP190101050A patent/AR114803A1/es unknown
- 2019-04-22 CN CN201980026036.8A patent/CN111989322B/zh active Active
- 2019-04-22 US US16/390,815 patent/US11358952B2/en active Active
-
2020
- 2020-10-15 CO CONC2020/0012824A patent/CO2020012824A2/es unknown
- 2020-10-16 CL CL2020002696A patent/CL2020002696A1/es unknown
- 2020-10-22 MX MX2023005160A patent/MX2023005160A/es unknown
-
2022
- 2022-05-12 US US17/743,313 patent/US11945804B2/en active Active
-
2023
- 2023-06-05 AU AU2023203504A patent/AU2023203504A1/en active Pending
-
2024
- 2024-03-18 JP JP2024041949A patent/JP2024073590A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2019209692A5 (fr) | ||
| HRP20231199T1 (hr) | Supstituirani spojevi 4-aminoizoindolin-1,3-diona i njihova upotreba za liječenje limfoma | |
| AU2020368542B2 (en) | Bifunctional molecules containing an E3 ubiquitine ligase binding moiety linked to a BCL6 targeting moiety | |
| AU2021202962C1 (en) | Isoindolinone inhibitors of the MDM2-p53 interaction having anticancer activity | |
| AU2017382436B2 (en) | Compounds and methods for the targeted degradation of Rapidly Accelerated Fibrosarcoma polypeptides | |
| KR102642203B1 (ko) | 급속 진행형 섬유육종 폴리펩티드의 표적화 분해를 위한 다중 고리 화합물 및 방법 | |
| RU2213089C2 (ru) | Моноциклические бензамиды производных 3- или 4-замещенного 4-(аминометил)пиперидина, способы их получения, фармацевтическая композиция, способ ее приготовления, производное карбоновой кислоты | |
| JP2018520105A5 (fr) | ||
| BR112019015312A2 (pt) | Moduladores da proteólise pelo receptor de estrogênio e métodos de uso associados | |
| ES2580961T3 (es) | Derivados Tiazolilfenil-bencenosulfonamido como Inhibidores de Cinasa | |
| RU2330019C2 (ru) | Производные пиперидина, способ их получения, фармацевтическая композиция на их основе и способ лечения хемокин-опосредованного болезненного состояния с их использованием | |
| ES2672992T3 (es) | Compuesto aromático | |
| JP2007524696A5 (fr) | ||
| WO2014033631A1 (fr) | N- (3-pyridyl)-biarylamides en tant qu'inhibiteurs de kinase | |
| WO2022087125A1 (fr) | Composés et procédés pour la dégradation ciblée de protéine du récepteur des androgènes | |
| WO2013175388A1 (fr) | Nouveaux n-pyridinylamides substitués par un cycle à titre d'inhibiteurs de kinase | |
| CA2709786A1 (fr) | 4-(4-cyano-2-thioaryle)-dihydropyrimidinone et son utilisation | |
| TW201726647A (zh) | 醫藥化合物 | |
| JP2005525341A5 (fr) | ||
| WO2014099880A1 (fr) | Composés de pyridazine bicycliques condensés substitués par un groupe aryle | |
| WO2022047145A1 (fr) | Composés de dégradation de protéine de fibrosarcome rapidement accéléré et leurs procédés d'utilisation | |
| IL84504A (en) | History of benzimidazole preparation and pharmaceutical preparations containing them | |
| WO2014033630A1 (fr) | Nouveaux carboxamides d'aminothiazole en tant qu'inhibiteurs de kinase | |
| AU2020410514A1 (en) | 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | |
| EP3116862A1 (fr) | Dérivés de pipérazine utilisés en tant qu'inhibiteurs de la protéase du vih |